Morning Chronotype Decreases the Risk of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer
- PMID: 35132840
- PMCID: PMC8822114
- DOI: 10.3346/jkms.2022.37.e34
Morning Chronotype Decreases the Risk of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer
Abstract
Background: The purpose of this longitudinal prospective cohort study was to investigate the role of chronotype in the incidence of chemotherapy-induced peripheral neuropathy (CIPN) among women with breast cancer.
Methods: We recruited women with breast cancer awaiting adjuvant chemotherapy, including four cycles of docetaxel. Participants reported peripheral neuropathy symptoms of numbness/tingling at the baseline, and at 4weeks after completion of chemotherapy. Candidate psychiatric factors associated with CIPN were assessed at the baseline, using the Composite Scale of Morningness, the Pittsburgh Sleep Quality Index, and the Hospital Anxiety and Depression Scale. To examine the association between chronotype and CIPN, we built logistic regression models, adjusting for demographic, clinical, and other psychiatric variables.
Results: Among 48 participants, 29 participants developed CIPN. The morning chronotype was inversely associated with CIPN (odds ratio, 0.06; confidence interval, 0.01-0.74; P = 0.028) after adjusting for age, BMI, education, type of operation, alcohol use, smoking, sleep quality, depression, and anxiety.
Conclusion: Our results suggest that the morning chronotype is a protective factor against the development of CIPN in patients with breast cancer who were treated with docetaxel.
Trial registration: ClinicalTrials.gov Identifier: NCT01887925.
Keywords: Adjuvant Chemotherapy; Breast Cancer; Chemotherapy-Induced Peripheral Neuropathy; Chronotype.
© 2022 The Korean Academy of Medical Sciences.
Conflict of interest statement
The authors have no potential conflicts of interest to disclose.
Figures
Similar articles
-
Morning chronotype is a protective factor against chemotherapy-induced hot flashes in premenopausal women with breast cancer.Support Care Cancer. 2020 Mar;28(3):1351-1358. doi: 10.1007/s00520-019-04949-0. Epub 2019 Jul 1. Support Care Cancer. 2020. PMID: 31264189
-
Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer.J Psychosom Res. 2018 May;108:14-19. doi: 10.1016/j.jpsychores.2018.02.012. Epub 2018 Feb 21. J Psychosom Res. 2018. PMID: 29602320
-
Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy.Breast Cancer Res Treat. 2021 Sep;189(2):521-532. doi: 10.1007/s10549-021-06304-6. Epub 2021 Jun 30. Breast Cancer Res Treat. 2021. PMID: 34191201 Free PMC article.
-
A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.Cancer. 2012 Apr 15;118(8 Suppl):2250-60. doi: 10.1002/cncr.27463. Cancer. 2012. PMID: 22488699 Review.
-
Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.Support Care Cancer. 2018 Apr;26(4):1051-1059. doi: 10.1007/s00520-017-4028-6. Epub 2017 Dec 26. Support Care Cancer. 2018. PMID: 29280005
Cited by
-
Relationship between BMI and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis.World J Surg Oncol. 2025 Mar 8;23(1):77. doi: 10.1186/s12957-025-03716-2. World J Surg Oncol. 2025. PMID: 40055767 Free PMC article.
References
-
- Phillips JL, Currow DC. Cancer as a chronic disease. Collegian. 2010;17(2):47–50. - PubMed
-
- Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9–17. - PubMed
-
- Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, et al. NCCN Task Force Report: Management of Neuropathy in Cancer. J Natl Compr Canc Netw. 2009;7(Suppl 5):S1–26. - PubMed
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical